Scanlan Sean F. 4
4 · TREACE MEDICAL CONCEPTS, INC. · Filed Mar 19, 2025
Insider Transaction Report
Form 4
Scanlan Sean F.
Chief Innovation Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-17$1.05/sh+50,000$52,500→ 414,081 total - Sale
Common Stock
2025-03-17$7.97/sh−50,000$398,460→ 364,081 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-17−50,000→ 16,875 totalExercise: $1.05From: 2021-01-30Exp: 2027-01-30→ Common Stock (50,000 underlying)
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]Includes 325,098 restricted stock units.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $7.8800 to $8.0900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option vested in equal annual installments over 4 years, commencing on January 30, 2017 with the last installment vesting on January 30, 2021.